SAN FRANCISCO – Following uncertainty, suspense and surprise in the heady political dramas around health care – outside of drug pricing controversies – predicting what else would unfold has been a perilous business. Nonetheless, policy mavens looking ahead to 2018 at the BIO Investor Forum gave it a go on Wednesday.